• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Enveric Biosciences Inc (NQ: ENVB )

    0.4900 -0.0092 (-1.84%)
    Streaming Delayed Price Updated: 11:45 AM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Enveric Biosciences Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
    Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
    From Enveric Biosciences
    Via Business Wire
    Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
    Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning. 
    Via InvestorPlace
    Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
    Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. 
    Via Benzinga
    Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
    From Enveric Biosciences
    Via Business Wire
    Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
    Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being... 
    Via Benzinga
    Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
    From Enveric Biosciences
    Via Business Wire
    Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Enveric Biosciences
    Via Business Wire
    Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
    From Enveric Biosciences
    Via Business Wire
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
    ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
    From Enveric Biosciences
    Via Business Wire
    Why Is Imunon (IMNN) Stock Up 259% Today?
    Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial. 
    Via InvestorPlace
    Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
    Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year. 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning! 
    Via InvestorPlace
    Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
    Via Benzinga
    Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
    From Enveric Biosciences
    Via Business Wire
    Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
    From Enveric Biosciences
    Via Business Wire
    New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
    Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Enveric Biosciences Announces Patent Granted for Drug Candidate
    From Enveric Biosciences
    Via Business Wire
    Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
    From Enveric Biosciences
    Via Business Wire
    Enveric Biosciences to Participate in BIO International Convention 2024
    From Enveric Biosciences
    Via Business Wire
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024
    ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
    Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the... 
    Via Benzinga
    Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
    From Enveric Biosciences
    Via Business Wire
    Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
    Via Benzinga
    Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
    From Enveric Biosciences
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.